Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier va...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2024
|
| _version_ | 1824458690483191808 |
|---|---|
| author | Lugano, D Kutima, B Kimani, M Sigilai, A Gitonga, J Karani, A Akech, D Karia, B Ziraba, AK Maina, A Lambisia, A Omuoyo, D Mugo, D Lucinde, R Owuor, S Konyino, G Newman, J Bailey, D Nduati, E Githinji, G Agoti, CN Bejon, P Scott, JAG Agweyu, A Warimwe, GM |
| author_facet | Lugano, D Kutima, B Kimani, M Sigilai, A Gitonga, J Karani, A Akech, D Karia, B Ziraba, AK Maina, A Lambisia, A Omuoyo, D Mugo, D Lucinde, R Owuor, S Konyino, G Newman, J Bailey, D Nduati, E Githinji, G Agoti, CN Bejon, P Scott, JAG Agweyu, A Warimwe, GM |
| author_sort | Lugano, D |
| collection | OXFORD |
| description | Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and October 2024 using sera from representative samples of the Kenyan population. From our genomics data, we identified the most prevalent Kenyan and global variants and performed pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show that antibodies from individuals in the general population in Kenya were less effective against the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1) compared to the ancestral wildtype strain. Although there was increased neutralization following multiple doses of vaccine, antibodies from > 40% of the vaccinated individuals did not neutralize the omicron variants, suggesting that individuals were susceptible to infection by these variants. |
| first_indexed | 2025-02-19T04:29:54Z |
| format | Journal article |
| id | oxford-uuid:66966c64-65e5-4f5e-ae09-25b6204608ef |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:29:54Z |
| publishDate | 2024 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:66966c64-65e5-4f5e-ae09-25b6204608ef2024-12-29T20:05:43ZEvaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in KenyaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:66966c64-65e5-4f5e-ae09-25b6204608efEnglishJisc Publications RouterBioMed Central2024Lugano, DKutima, BKimani, MSigilai, AGitonga, JKarani, AAkech, DKaria, BZiraba, AKMaina, ALambisia, AOmuoyo, DMugo, DLucinde, ROwuor, SKonyino, GNewman, JBailey, DNduati, EGithinji, GAgoti, CNBejon, PScott, JAGAgweyu, AWarimwe, GMIncreased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and October 2024 using sera from representative samples of the Kenyan population. From our genomics data, we identified the most prevalent Kenyan and global variants and performed pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show that antibodies from individuals in the general population in Kenya were less effective against the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1) compared to the ancestral wildtype strain. Although there was increased neutralization following multiple doses of vaccine, antibodies from > 40% of the vaccinated individuals did not neutralize the omicron variants, suggesting that individuals were susceptible to infection by these variants. |
| spellingShingle | Lugano, D Kutima, B Kimani, M Sigilai, A Gitonga, J Karani, A Akech, D Karia, B Ziraba, AK Maina, A Lambisia, A Omuoyo, D Mugo, D Lucinde, R Owuor, S Konyino, G Newman, J Bailey, D Nduati, E Githinji, G Agoti, CN Bejon, P Scott, JAG Agweyu, A Warimwe, GM Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya |
| title | Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya |
| title_full | Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya |
| title_fullStr | Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya |
| title_full_unstemmed | Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya |
| title_short | Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya |
| title_sort | evaluation of population immunity against sars cov 2 variants eg 5 1 fy 4 ba 2 86 jn 1 jn 1 4 and kp 3 1 1 using samples from two health demographic surveillance systems in kenya |
| work_keys_str_mv | AT luganod evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT kutimab evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT kimanim evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT sigilaia evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT gitongaj evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT karania evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT akechd evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT kariab evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT zirabaak evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT mainaa evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT lambisiaa evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT omuoyod evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT mugod evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT lucinder evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT owuors evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT konyinog evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT newmanj evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT baileyd evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT nduatie evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT githinjig evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT agoticn evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT bejonp evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT scottjag evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT agweyua evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya AT warimwegm evaluationofpopulationimmunityagainstsarscov2variantseg51fy4ba286jn1jn14andkp311usingsamplesfromtwohealthdemographicsurveillancesystemsinkenya |